Missing Data Methods in HIV Clinical Trials: Regulatory Guidance And Alternative Approaches

被引:0
|
作者
Thomas Kelleher
Alexandra Thiry
Richard Wilber
Anne Cross
机构
[1] Dept. 703,Pharmaceutical Research Institute
[2] Bristol-Myers Squibb Company,undefined
来源
Drug information journal : DIJ / Drug Information Association | 2001年 / 35卷
关键词
Missing data; HIV; Clinical trials; Regulatory guidance;
D O I
暂无
中图分类号
学科分类号
摘要
Efficacy in HIV clinical trials is measured by changes in HIV RNA levels over time as well as the proportion of subjects with HIV RNA levels below an assay’s threshold of reliable quantification at a single time point. Missing data arise naturally due to missed visits and premature discontinuations of treatment. The available data are then analyzed using repeated measures models and univariate comparisons of proportions, assuming missing data occur at random or considering missing values as treatment failures (worst case scenario). These and other methods recently proposed by regulatory authorities are presented along with alternative approaches. Advantages and disadvantages of each method are discussed. Data from a recent comparison of ’ standard-of-care’ triple combination regimens are used for illustration.
引用
收藏
页码:1363 / 1371
页数:8
相关论文
共 50 条
  • [31] Missing data in clinical trials for weight management
    McEvoy, Bradley W.
    JOURNAL OF BIOPHARMACEUTICAL STATISTICS, 2016, 26 (01) : 30 - 36
  • [32] The Prevention and Treatment of Missing Data in Clinical Trials
    Little, Roderick J.
    D'Agostino, Ralph
    Cohen, Michael L.
    Dickersin, Kay
    Emerson, Scott S.
    Farrar, John T.
    Frangakis, Constantine
    Hogan, Joseph W.
    Molenberghs, Geert
    Murphy, Susan A.
    Neaton, James D.
    Rotnitzky, Andrea
    Scharfstein, Daniel
    Shih, Weichung J.
    Siegel, Jay P.
    Stern, Hal
    NEW ENGLAND JOURNAL OF MEDICINE, 2012, 367 (14): : 1355 - 1360
  • [33] ASSESSING THE IMPLEMENTABILITY OF REGULATORY AGENCIES' GUIDANCE ON DIVERSITY IN CLINICAL TRIALS
    Metcalfe, R.
    Reshef, S.
    Park, J.
    VALUE IN HEALTH, 2024, 27 (06) : S209 - S209
  • [34] Approaches to Data Analyses of Clinical Trials
    Furberg, Curt D.
    Friedman, Lawrence M.
    PROGRESS IN CARDIOVASCULAR DISEASES, 2012, 54 (04) : 330 - 334
  • [35] MISSING INACTION: PREVENTING MISSING OUTCOME DATA IN RANDOMIZED CLINICAL TRIALS
    Wittes, Janet
    JOURNAL OF BIOPHARMACEUTICAL STATISTICS, 2009, 19 (06) : 957 - 968
  • [36] Appropriate pharmacogenomic approaches in clinical trials for regulatory submission
    Uyama, Y
    JOURNAL OF PHARMACOLOGICAL SCIENCES, 2005, 97 : 46P - 46P
  • [37] Commentary for the Missing Data Working Group's perspective for regulatory clinical trials, estimands, and sensitivity analyses
    Koch, Gary G.
    Wiener, Laura Elizabeth
    STATISTICS IN MEDICINE, 2016, 35 (17) : 2887 - 2893
  • [38] An Alternative Way to Classify Missing Data Mechanism in Clinical TrialsA Dialogue on Missing Data
    Wei, Lynn
    JOURNAL OF BIOPHARMACEUTICAL STATISTICS, 2011, 21 (02) : 355 - 361
  • [39] Methods for imputing missing data for Parkinson's disease clinical trials with multiple correlated outcomes
    Luo, S.
    He, B.
    Elm, J.
    Tilley, B.
    MOVEMENT DISORDERS, 2013, 28 : S170 - S170
  • [40] Methods for Missing Data Handling in Phase III Clinical Trials with Nonnormal Endpoints and Nonnormal Covariates
    Fan, Chunpeng
    Wei, Lynn
    Koch, Gary G.
    STATISTICS IN BIOPHARMACEUTICAL RESEARCH, 2020, 12 (01): : 68 - 78